Scientists are exploring a groundbreaking approach to combat heart disease through gene editing. This innovative treatment targets high cholesterol, potentially offering a one-time solution rather than the ongoing need for medication. Though research is still in its early stages, with trials conducted on a limited number of participants, initial results are promising. Companies like CRISPR Therapeutics and Verve Therapeutics are leading the charge, hinting that disabling specific genes could significantly reduce harmful cholesterol levels in the body.
Dr. Luke Laffin, a preventive cardiologist at the Cleveland Clinic, emphasized the demand for a lasting solution, stating, “People want a fix, not a bandage.” Following a study published in the New England Journal of Medicine, he received numerous inquiries from individuals eager to participate in upcoming clinical trials. Cholesterol is essential for bodily functions, but excessive amounts, particularly low-density lipoprotein (LDL) cholesterol, contribute to plaque buildup in arteries, a primary cause of heart attacks and strokes.
Cardiovascular disease remains the leading cause of death worldwide, prompting millions to rely on medications like statins to lower their cholesterol. Yet, many individuals find it challenging to maintain their cholesterol levels even with medication, often discontinuing due to side effects and the lifelong commitment required.
The Genetic Link to Cholesterol Levels
Research indicates that while dietary choices influence cholesterol levels, the liver plays a crucial role in cholesterol production. Genetic factors also contribute significantly to how cholesterol is processed in the body. Some individuals inherit genes that lead to dangerously high cholesterol, while others naturally maintain low levels throughout their lives.
Dr. Kiran Musunuru, now a cardiologist at the University of Pennsylvania, has previously identified that certain individuals with exceptionally low cholesterol possess a mutation that disables the ANGPTL3 gene. This mutation not only lowers LDL cholesterol but also reduces triglycerides, another type of harmful fat. Additionally, researchers at UT Southwestern Medical Center discovered that some people’s low LDL levels result from a malfunction in the PCSK9 gene.
Dr. Steven Nissen from the Cleveland Clinic noted, “It’s a natural experiment in what would happen if we actually changed the gene.” With funding from Swiss-based CRISPR Therapeutics, Nissen and Laffin spearheaded a study focusing on the ANGPTL3 gene.
Initial Findings and Future Prospects
Current treatments include injectable medications that inhibit proteins produced by the PCSK9 and ANGPTL3 genes, helping the body eliminate cholesterol. The new research employs the CRISPR gene-editing technology to disable these genes in individuals at high risk for uncontrolled cholesterol.
In one study, 15 adults received a single infusion of nanoparticles containing the CRISPR tool, targeting the ANGPTL3 gene in the liver. Results showed that within two weeks, those receiving the highest doses experienced a significant reduction in both LDL and triglyceride levels, with reductions of approximately 50%. Verve Therapeutics also reported similar outcomes in its PCSK9-focused study.
These initial trials took place in Australia, the United Kingdom, and other locations, with a representative from Eli Lilly, Verve’s parent company, stating that U.S. study sites will soon commence. Dr. Nissen indicated that further studies surrounding CRISPR Therapeutics’ approach are expected to begin this year.
While the promise of gene editing appears significant, experts stress the need for extensive long-term studies involving more participants. Dr. Musunuru, a co-founder of Verve, noted that some participants from earlier studies have been monitored for up to two years, showing sustained reductions in cholesterol levels. Given that gene editing is viewed as a permanent alteration, any modified liver cells would continue to replicate with the edited genes.
Despite the excitement surrounding gene editing, safety concerns remain paramount. Dr. Joseph Wu of Stanford University, who did not participate in the studies, highlighted the necessity for thorough investigations into the long-term safety of CRISPR-based therapies. There are risks associated with the particles used to deliver the gene-editing tools, which may cause liver irritation or inflammation. Questions also persist regarding the precision of gene editing and whether it exclusively targets the intended genes.
As researchers work towards refining these gene-editing strategies, the American Heart Association advises individuals to focus on eight key factors for improving heart health. These include maintaining a heart-healthy diet rich in fruits, vegetables, whole grains, and healthy fats, alongside regular physical activity, weight management, and avoiding smoking.
Controlling blood pressure is essential, with optimal readings below 120 over 80, as is managing blood sugar levels to mitigate the effects of diabetes on heart health. For those with high cholesterol, guidelines recommend lowering LDL levels to at least 70 mg/dL, with targets being even lower for individuals at the highest risk.
As scientists continue to investigate gene-editing techniques, the potential for a revolutionary shift in heart disease treatment remains on the horizon.
